The Association of European Cancer Leagues, a nonprofit, pan-European organization of national and regional cancer societies, has issued a new white paper that calls for greater biosimilar use as a means to reduce costs and increase patient access to cancer treatment.
The Association of European Cancer Leagues, a nonprofit, pan-European organization of national and regional cancer societies, has issued a new white paper that calls for greater biosimilar use as a means to reduce costs and increase patient access to cancer treatment.
The white paper begins on a sobering note, highlighting the fact that substantial disparities exist in patient access to cancer therapies among European nations; many biologics available in Western European countries are not available, or not reimbursed, in Eastern Europe, and even within individual nations, access to drugs can vary widely by region. The ever-rising cost of therapies is a primary driver of these disparities, say the authors.
One factor keeping prices high is the landscape of intellectual property protections that, while less challenging than in the United States, still contributes to an uncertain market for biosimilars. In the European context, Supplementary Protection Certificates (SPCs), which grant 5 added years of patent protection to drugs, are one key blockade to biosimilar market entry.
Post-launch, however, uptake of anticancer biosimilars has been relatively slow, and that fact, argues the paper, is one reason that the cost of cancer treatment remains high. The authors point to differences in pricing and reimbursement policies across different nations as a key issues hampering uptake, but they indicate that the main hurdle for biosimilars is a lack of knowledge and education among key stakeholders—especially providers and patients—which effectively blocks informed decision-making about using these drugs.
The white paper calls for “precise and reliable information from independent institutions and better communication and education on the use of biosimilars” as a way to overcome this obstacle to cost savings. It also calls for support for substitution and switching programs on an EU-wide level.
The white paper’s authors make 5 specific recommendations to encourage biosimilar use after authorization. First, question-and-answer documents and knowledge-sharing platforms on biosimilars must be developed. Second, quotas or gain-sharing policies must be implemented related to physicians’ prescribing practices. Third, the European Medicines Agency should develop guidelines for switching, and such guidance should be published in a biosimilar’s European public assessment report summary and in its product label. Fourth, switching programs should be supported by payers and industry, and biosimilar use should be discussed in clinical prescribing guidelines. Fifth, national and European medical societies should offer guidance and trainings for their members, and patient organizations should also raise awareness among their members, according to the paper.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.